Alembic Pharmaceuticals Limited — Important, 23-11-2024: General Updates

US FDA conducted a scheduled GMP inspection at Alembic Pharmaceuticals' Solid Oral Formulation Facility (F-4) in Jarod, resulting in a Form 483 with five procedural observations. Alembic Pharmaceuticals is committed to addressing these observations and will submit a detailed response within the specified timeline. The company emphasizes its dedication to upholding stringent quality standards and regulatory compliance. Investors should monitor this situation closely, as addressing the observations promptly will be crucial for maintaining the facility's operational viability and reputation.